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Background

Case

Treatment for GCT

 Giant cell tumor (GCT): Rare
 Accounts for about 1.4 %, 9.4 % of
primary spine tumors
 Classified as benign, but has the
characteristic of aggressiveness
 Potential to metastasize
 Common site of metastasis = Lung
 Mets usually seen in patients with
advanced or recurrent disease

 52-year-old male
 1–2-year history of left lateral thigh
pain, worse at night
 MRI revealed a sacral mass
 CT guided biopsy confirmed giant cell
tumor

 Surgery # 1 goal
 Systemic therapy = Denosumab
 If en bloc resection is not achieved the recurrence rate
ranges from 22.4 % to 41.7%
 Radiation
 Serial embolization
 Combination-multidisciplinary approach

Objectives
o Discuss the prevalence of giant
cell tumor of the spine
o Review the common treatments for
giant cell tumor of the spine and
sacrum
o Discuss the role of Advance
Practice Provider in the
management of these patients

Radiographic Appearance
MRI:
• Heterogeneous
• Expansible osteocytes lesion
• Low-intermediate signal intensity on
T2 weighted images
• Cause vertebral body collapse
• Soap bubble appearance

Post Resection

Implications for APPs
 Care coordination amongst the
multidisciplinary team including
surgery, Sarcoma, Pain, IR and
Radiation
 Instrumental in educating the patient
on disease, hospitalization, preoperative process, admission,
disability, post-operative process and
long -term complications due to
neurological deficits
 Management of surgical and
neurological complications
 Manage long term neurological
symptoms and coordinate
multidisciplinary long-term follow-ups

Denosumab

 Monoclonal Ab against RANKL (receptor activator of
nuclear factor-kappa beta ligand)
 RANKL expressed on neoplastic stromal cells and
multinucleated giant cells of GCT mediate bone resorption
 Denosumab inhibits RANKL decreasing bone turnover
and reproduction of multinucleated giant cells
 Most successfully used therapy and extensively studied
 Increases bone formation
 Tumor reduction
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Post Treatment

GCT of the Spine
 Most common site of giant cell
tumor = sacrum
 Sacrum accounts for
approximately 2-8 % GCTs
 Above the sacrum next lumbar and
thoracic spine
 Rarely the cervical spine
 Affect more females than males:
2:1 ratio
 Age: 20-40 years

Axial T1 w/wo contrast
MRI sacrum w/wo contrast

Axial T2 MRI

CT:
• Soft tissue attenuation
• No mineralized matrix
• Lytic area
• Sclerotic margins,
hemorrhage or necrosis

CT post Denosumab
and embolization
Evidence of increase
bone formation

